Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

34.47
+0.06200.18%
Post-market: 34.46-0.0120-0.03%19:30 EDT
Volume:17.43K
Turnover:602.34K
Market Cap:95.83M
PE:- -
High:34.93
Open:34.93
Low:34.46
Close:34.41
52wk High:36.84
52wk Low:23.42
Shares:2.78M
Float Shares:2.78M
Volume Ratio:0.82
T/O Rate:0.63%
Dividend:0.26
Dividend Rate:0.75%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Royalty Pharma Falls After Novartis' Cholesterol Drug Fails in Study

Reuters
·
Sep 09

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

AstraZeneca's COPD Candidate Shows Strong Results in Late-Stage Trials, Reviving a Once-Doubted Drug Target

Deep News
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Chengdu Easton Biopharmaceuticals Schedules Participation in Semi-Annual Innovation Drug Sector Earnings Call

Deep News
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08

Political and General News Events from September 8

Reuters
·
Sep 08